HC Wainwright Comments on Eyenovia FY2029 Earnings

Eyenovia, Inc. (NASDAQ:EYEN) – Equities researchers at HC Wainwright issued their FY2029 earnings per share estimates for shares of Eyenovia in a report released on Thursday, February 6th. HC Wainwright analyst M. Caufield forecasts that the company will post earnings of $1.40 per share for the year. HC Wainwright currently has a “Neutral” rating and a $2.00 target price on the stock. The consensus estimate for Eyenovia’s current full-year earnings is ($0.52) per share.

Several other research analysts have also recently weighed in on the company. William Blair restated a “market perform” rating on shares of Eyenovia in a research note on Friday, November 15th. LADENBURG THALM/SH SH reissued a “neutral” rating on shares of Eyenovia in a research report on Monday, November 18th. Finally, Brookline Capital Management reaffirmed a “hold” rating on shares of Eyenovia in a report on Friday, November 15th.

Eyenovia Stock Performance

EYEN stock opened at $2.04 on Friday. The stock’s 50 day simple moving average is $6.67 and its 200 day simple moving average is $33.30. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.58. Eyenovia has a 12-month low of $2.01 and a 12-month high of $205.60. The stock has a market capitalization of $227.32 million, a PE ratio of -2.79 and a beta of 1.25.

Eyenovia (NASDAQ:EYEN) last issued its earnings results on Tuesday, November 12th. The company reported ($8.80) earnings per share (EPS) for the quarter, topping the consensus estimate of ($10.40) by $1.60. Eyenovia had a negative net margin of 114,639.41% and a negative return on equity of 1,108.24%. During the same period in the prior year, the firm earned ($14.40) EPS.

Institutional Trading of Eyenovia

Large investors have recently modified their holdings of the company. Geode Capital Management LLC lifted its holdings in Eyenovia by 36.6% in the third quarter. Geode Capital Management LLC now owns 557,994 shares of the company’s stock valued at $288,000 after acquiring an additional 149,471 shares during the period. Nations Financial Group Inc. IA ADV boosted its stake in shares of Eyenovia by 78.6% during the 3rd quarter. Nations Financial Group Inc. IA ADV now owns 90,900 shares of the company’s stock worth $47,000 after acquiring an additional 40,000 shares during the last quarter. Finally, Financial Management Network Inc. bought a new stake in shares of Eyenovia during the 3rd quarter valued at $39,000. Institutional investors own 25.84% of the company’s stock.

Eyenovia Company Profile

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.